Cellectis S.A.CC

Cellectis S.A.

1.79USDR
−0.06−3.24%
As of today at 16:25 UTC
USD
No trades
See on Supercharts

CLLS fundamentals

Key facts

Market capitalization‪131.61 M‬USD
Basic EPS (TTM)−1.03USD
Founded1999
CEOAndré Choulika
About

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Ownership
‪‪72.09 M‬‬
Free Float shares
‪‪69.26 M‬‬ (96.07%)
Closely held shares
‪‪2.84 M‬‬ (3.93%)
Free Float shares
‪‪69.26 M‬‬ (96.07%)
Closely held shares
‪‪2.84 M‬‬ (3.93%)
Capital structure
Market cap
‪‪131.61 M‬‬
Debt
‪‪112.12 M‬‬
Cash & equivalents
‪‪260.95 M‬‬
Enterprise value
‪‪−17.23 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪131.61 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
6.37x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
6.37x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪80.00‬
‪160.00‬
‪240.00‬
‪320.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−24,000%‬
‪−16,000%‬
‪−8,000%‬
‪0%‬
‪8,000%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−51.00 M‬‬
‪‪−34.00 M‬‬
‪‪−17.00 M‬‬
‪0.00‬
‪‪17.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−26.00 M‬‬
‪‪−13.00 M‬‬
‪0.00‬
‪‪13.00 M‬‬
‪‪26.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−24.00 M‬‬
‪‪−12.00 M‬‬
‪0.00‬
‪‪12.00 M‬‬
‪‪24.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Therapeutics
By country
Period: 2023
France

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
‪‪18.00 M‬‬
‪‪24.00 M‬‬
Actual
Estimate
Earnings
Next:Feb 26
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.75‬
‪−0.50‬
‪−0.25‬
‪0.00‬
‪0.25‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

CLLS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
‪‪320.00 M‬‬
Assets
Liabilities